Mobocertinib

LuciMob (Mobocertinib) is a targeted therapy developed for adults with non-small cell lung cancer (NSCLC) that has spread locally or to other parts of the body (metastatic).
It is specifically designed to treat patients whose tumors have a mutation in the EGFR gene known as an exon 20 insertion.

COMPOSITION:

Each LuciMob capsule contains: 48.06mg Mobocertinib succinate equivalent to Mobocertinib 40mg

INDICATION:

LuciMob is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

DOSAGE AND USE:

The recommended dosage of LuciMob is 160 mg orally once daily until disease progression or unacceptable toxicity.

Capsule should be swallowed whole & not chewed or crushed.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of the reach of Children. Do not administered LuciMob in Pregnancy and Lactation patient treatment.